Business Model:
Revenue: $0
Employees: 0-0
Address:
City:
State:
Zip:
Country:
Quaker BioVentures is a venture capital firm investing in life science companies. The firm leads investments across the spectrum of the life science industry, including biopharmaceuticals, medical devices, human diagnostics, specialty pharmaceuticals, and healthcare services. Quaker BioVentures invests in companies at all stages of development, from early stage start-ups to public companies. Founded in 2003, the firm is currently investing Quaker BioVentures II, a $420 million fund formed in 2007. Quaker BioVentures manages over $700 million in committed capital.
Contact Phone:
Contact Email:
Announced Date | Company | Transaction | Money Raised |
---|---|---|---|
10/2007 | Optherion | Series A | 37M |
8/2010 | Achillion Pharmaceuticals | Post-IPO Equity | 50.1M |
1/2011 | RainDance Technologies | Series D | 37.5M |
10/2009 | Sleep Solutions | Series F | 20M |
11/2007 | Tranzyme | Venture Round | 20M |
10/2008 | Biolex Therapeutics | Series D | 0 |
9/2012 | Intact Vascular | Series A | 15.5M |
8/2003 | Biolex Therapeutics | Venture Round | 0 |
5/2005 | Celator Pharmaceuticals | Series B | 20M |
10/2009 | Neuronetics | Series D | 0 |
1/2011 | TetraLogic Pharmaceuticals | Series C | 0 |
12/2009 | Regado Biosciences | Series D | 0 |
10/2008 | Corridor Pharmaceuticals | Seed Round | 0 |
6/2007 | Argolyn Bioscience | Series A | 15.8M |
3/2006 | Nitric Bio | Series A | 14M |
4/2004 | MedMark Treatment Centers | Venture Round | 28M |
12/2002 | BioRexis | Series A | 8M |
11/2008 | Tengion | Series C | 0 |
3/2007 | Regado Biosciences | Series C | 23M |
4/2013 | RainDance Technologies | Series E | 0 |
2/2005 | Neotropix | Series A | 10M |
3/2006 | Helomics | Venture Round | 20M |
6/2010 | Helomics | Series D | 33M |
8/2009 | Rapid Micro Biosystems | Series A | 18.6M |
1/2010 | Tarsa Therapeutics | Series A | 24M |
6/2006 | TetraLogic Pharmaceuticals | Series B | 36M |
6/2011 | NovaSom | Series D | 35M |
3/2004 | BioRexis | Series B | 30M |
7/2008 | Celator Pharmaceuticals | Series C | 22.5M |
3/2008 | EKR Therapeutics | Series D | 50M |
9/2013 | PreCision Dermatology | Debt Financing | 67M |
6/2006 | Tengion | Series B | 50M |
8/2007 | Celator Pharmaceuticals | Series C | 10M |
9/2010 | Celator Pharmaceuticals | Series D | 0 |
10/2007 | Tengion | Series C | 33M |
9/2005 | Amicus Therapeutics | Series C | 55M |
1/2010 | BioLeap | Series A | 5M |
5/2010 | TearScience | Series C | 44.5M |
6/2004 | Nucleonics | Series B | 49.2M |
4/2005 | TargetRx | Series D | 0 |
9/2005 | Biolex Therapeutics | Series B | 36M |
6/2009 | Cempra | Series C | 46M |
8/2010 | TetraLogic Pharmaceuticals | Series C | 0 |
5/2011 | Neuronetics | Series E | 30M |
4/2015 | Neuronetics | Series F | 0 |
6/2010 | Corridor Pharmaceuticals | Series A | 0 |
5/2007 | Biolex Therapeutics | Series C | 30M |
4/2008 | Transave | Series D | 35M |
9/2006 | Amicus Therapeutics | Series D | 60M |
3/2012 | Tarsa Therapeutics | Series B | 28M |
11/2008 | Helomics | Venture Round | 43M |
10/2009 | Asensus Surgical | Post-IPO Equity | 0 |
3/2019 | Kaarta | Series A | 0 |
7/2008 | NuPathe | Series B | 30M |
8/2007 | EKR Therapeutics | Series C | 13M |
5/2005 | Tranzyme | Series A | - |
4/2008 | Diasome Pharmaceuticals | Series B | 8.4M |
4/2007 | StageMark | Series B | 1.6M |
3/2019 | Kaarta | Series A | 0 |
4/2015 | Neuronetics | Series F | 0 |
9/2013 | PreCision Dermatology | Debt Financing | 0 |
4/2013 | RainDance Technologies | Series E | 0 |
9/2012 | Intact Vascular | Series A | 0 |
3/2012 | Tarsa Therapeutics | Series B | 0 |
6/2011 | NovaSom | Series D | 0 |
5/2011 | Neuronetics | Series E | 0 |
1/2011 | RainDance Technologies | Series D | 0 |
1/2011 | TetraLogic Pharmaceuticals | Series C | 0 |
Name | Price |
---|
Name | Size | Announced Date |
---|